<DOC>
	<DOC>NCT00406588</DOC>
	<brief_summary>This study is a multicenter, randomized, double blind, parallel group study of 3 months' treatment with SLV308 administered as a monotherapy in patients with advance stage PD. An open label safety extension to this study is planned as a separate protocol for patients who are willing and eligible to participate.</brief_summary>
	<brief_title>SLV308 for Treatment of Patients With Parkinson's Disease Experiencing Motor Fluctuations</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Levodopa</mesh_term>
	<criteria>Diagnosis of idiopathic Parkinson's Disease, advance stage of disease, Modified Hoehn &amp; Yahr stage IIIV, presence of a recognizable 'on' and 'off' state (motor fluctuations) and stable treatment with levodopa for at least 28 days prior to randomization 'onoff' phenomena or 'yoyoing' and/or an abrupt unpredictable loss of efficacy unrelated to the timing of LDOPA administration, Prevalent expression of troublesome dyskinesias during 'on' time at waking hours, Diagnosis is unclear or a suspicion of other parkinsonian syndromes exists, Previous surgery for the treatment of PD</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2008</verification_date>
	<keyword>Parkinson Disease</keyword>
</DOC>